Partnership with Accelovance and MMP for US studies
Immunicum AB (publ), today announced the establishment of a clinical development services agreement with Accelovance to advance the Company’s lead cancer immune primer, INTUVAX, into the US in kidney cancer and in melanoma. Through this agreement, Accelovance, a Contract Research Organization (CRO), will support Immunicum’s clinical development strategies by offering scientific, medical and regulatory expertise, in addition to providing support through Project Management, Clinical Monitoring, Data Management, Biostatistics, and Safety services for Immunicum’s clinical trials in the US. The agreement will also provide access to Accelovance’s Preferred Sites Network via their association with the US Based non-profit, Midwest Melanoma Partnership (MMP). Lead Investigator in the US, Dr. Arkadiusz Dudek, Director of the Oncology Clinical Trials Office at the University of Illinois’ College of Medicine, has many years of experience in immuno-oncology and has previously conducted clinical trials in kidney cancer and melanoma.
Read the press release here: Press release 160517 – Immunicum Announces MMP and Accelovance Partnerships